• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital

tetano

Editor, Senior Moderator
J Med Virol


. 2021 May 9.
doi: 10.1002/jmv.27033. Online ahead of print.
SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital


Carola Holzner[SUP] 1 [/SUP], Dirk Pabst[SUP] 1 [/SUP], Olympia Evdoxia Anastasiou[SUP] 2 [/SUP], Ulf Dittmer[SUP] 2 [/SUP], Randi Katrin Manegold[SUP] 1 [/SUP], Joachim Risse[SUP] 1 [/SUP], David Fistera[SUP] 1 [/SUP], Clemens Kill[SUP] 1 [/SUP], Maximilian Falk[SUP] 1 [/SUP]



Affiliations

Abstract

The use of Antigen point of care tests (AgPOCT) might be an essential tool to fight the coronavirus disease 2019 (COVID-19) pandemic. Manufacturer information indicates a specificity of about 95% and there is a growing interest to use these tests area-wide. Therefore, it is necessary to clarify whether AgPOCT can be used safely for "rule-in" (detection of positive patients) and for "rule-out" (valid negative testing). Two thousand three hundred and seventy-five patients received polymerase chain reaction (PCR) testing and AgPOCT for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of symptoms. The positive predictive value of symptomatic and asymptomatic patients was compared with a cut-off threshold cycle (C[SUB]t[/SUB] ) value of ?30 and in total. Five hundrded and fifty-one patients tested positive for the SARS-CoV-2 virus by PCR, of whom 35.2% presented without symptoms. In all patients, regardless of their symptoms or C[SUB]t[/SUB] values, a sensitivity of 68.9% and a specificity of 99.6% were calculated for AgPOCT. In patients with C[SUB]t[/SUB] values ?30, a sensitivity of 80.5% (95% confidence interval: ?1.62) and a specificity of 99.6% were shown for all tests (symptomatic/asymptomatic). Highly infectious patients (C[SUB]t[/SUB] ? 20), regardless of symptoms, were reliably detected by the AgPOCT. In infectious patients with C[SUB]t[/SUB] values ?30, the test has a sensitivity of about 80% regardless of COVID-19 typical symptoms, which is apparently less than the 96.52% specificity indicated by the manufacturer. Relevant improvement in test sensitivity by querying the patients who are symptomatic and asymptomatic is also not feasible. We strongly suggest that we critically question the use of AgPOCT for "rule-out," as they only provide a supposed safety.

Keywords: SARS coronavirus; inflammation; pandemics.
 
Back
Top Bottom